The 3 + 3 design in dose-finding studies with small sample sizes: Pitfalls and possible remedies.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 350, doi. 10.1177/17407745241240401
- By:
- Publication type:
- Article
Works matching IS 17407745 AND DT 2024 AND VI 21 AND IP 3
Results: 14
1
2
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 267, doi. 10.1177/17407745241234652
- By:
- Publication type:
- Article
3
Applications of the partial-order continual reassessment method in the early development of treatment combinations.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 331, doi. 10.1177/17407745241234634
- By:
- Publication type:
- Article
4
The patient perspective on dose optimization for anticancer treatments: A new era of cancer drug dosing—Challenging the "more is better" dogma.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 358, doi. 10.1177/17407745241232428
- By:
- Publication type:
- Article
5
Dose optimization for cancer treatments with considerations for late-onset toxicities.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 322, doi. 10.1177/17407745231221152
- By:
- Publication type:
- Article
6
Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 298, doi. 10.1177/17407745231220661
- By:
- Publication type:
- Article
7
A review of patient recruitment in randomised controlled trials of preoperative exercise.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 371, doi. 10.1177/17407745231219270
- By:
- Publication type:
- Article
8
A pilot recruitment strategy to enhance ethical and equitable access to Covid-19 pediatric vaccine trials.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 390, doi. 10.1177/17407745231217299
- By:
- Publication type:
- Article
9
Risk–benefit trade-offs and precision utilities in phase I-II clinical trials.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 287, doi. 10.1177/17407745231214750
- By:
- Publication type:
- Article
10
Optimizing the doses of cancer drugs after usual dose finding.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 340, doi. 10.1177/17407745231213882
- By:
- Publication type:
- Article
11
Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 308, doi. 10.1177/17407745231212193
- By:
- Publication type:
- Article
12
Leveraging the functionality of Research Electronic Data Capture (REDCap) to enhance data collection and quality in the Opioid Analgesic Reduction Study.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 381, doi. 10.1177/17407745231212190
- By:
- Publication type:
- Article
13
Evaluating whether the proportional odds models to analyse ordinal outcomes in COVID-19 clinical trials is providing clinically interpretable treatment effects: A systematic review.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 363, doi. 10.1177/17407745231211272
- By:
- Publication type:
- Article
14
Statistical and practical considerations in planning and conduct of dose-optimization trials.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 273, doi. 10.1177/17407745231207085
- By:
- Publication type:
- Article